The positive clinical results of two treatments for lung cancer were published in the research and development daily Ermershadong K

2020.10.19 Research and Development NEWS: Eisai / Merca East K drug joint lenvatinib clinical data on the efficacy of 7 types of tumors was released for the first time; Roche / AbbVie Venclexta joint azacitdine treatment AML was approved in the United States; Hanyu pharmaceutical injection tracitum single anti-drug registration application was accepted; Capathamin tablets and other 14 generic drugs through consistency evaluation ... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original text) "Drug Research and Development" Weishi / Mercadon K drug combined with lunvatini for 7 types of tumor efficacy clinical data released for the first time Weishi and Mercadon recently released two LEAP trials (LEAP-004 and LEAP-004) clinical trial data, the research phase is in the clinical phase II.
combination therapy of the two is the immuno combination target therapy which is hot in tumor therapy research, and the combination of immuno combination target therapy has achieved good results in clinical trials of several different tumors.
announced the results of two of Keytruda's latest active clinical trials at the IASLC 2020 North American Lung Cancer Conference, Mercedon announced two positive clinical trial results for its anti-PD-1 therapy Keytruda to treat lung cancer clinical progress.
studies have shown significant improvements in the first-line treatment of advanced NSCLC with K-drug combination chemotherapy, and the combined use of quavonlimab and K-drug has an acceptable safety.
Drug Approval: New target CD40 "C-bit" out of THEX005M awarded the FDA Orphan Drug title is dedicated to the development of a new generation of antibody drugs for the treatment of diseases such as tumors clinical phase biopharmaceutical company Apixigen recently announced that its target CD40 monoclonal antibody APX005M was awarded the FDA's orphan drug qualification for the treatment of esophageal and gastroesophageal connectivity cancer and pancreatic cancer.
Roch/AbbVie Venclexta Combined Azacitidine Treatment AML was approved in the United States before Roche Group member Genentek announced that the FDA has fully approved Venclexta® combined azatsin, or dicytosine, or low-dose agalycosides, to treat patients 75 years of age or older newly diagnosed or suffering from co-diseases that prevent access to intensive-induced chemotherapy treatment for acute myeloid leukemia (AML).
Chengdu Bett hepatitis B heavy drug "Fumarate propofol ty nofowe tablets" was approved for the first time on the 19th, NMPA issued approvals, Chengdu Times 4 generic drugs "Fumarate propofol tynofove tablets" was approved for listing, while the same through consistent evaluation, become the first imitation in China.
Fosun Pharma: Hanyu Pharmaceutical injection with querceton single anti-drug registration supplementary application was accepted on the 19th, Shanghai Fosun Pharma (Group) Co., Ltd. holding subsidiary of Hanyu Pharmaceutical's injection quercetozhu single anti-new "60mg/ bottle" specifications by the State Drug Administration drug registration supplementary application review and acceptance.
Yuandong biological hair! Heng Rui just took the first imitation injection to welcome the second recent NMPA official website data show that Chengdu Yuandong Biopharmaceutical's Grombrom ammonium injection class 3 imitation listing application has entered the "in the approval" state, Hengrui Pharmaceutical won the first imitation after the second.
Haussen Pharmaceuticals Shagritin tablets 4 generic drugs into the approval status recently, NMPA official website data show that Haussen Pharmaceuticals Shagritin tablets 4 generic market applications have entered the "in the approval" state.
Shagritin is AstraZeneta's oral anti-sugar drug, with terminal sales of more than 500 million yuan in China's public medical institutions in 2019, Osaikang won the first imitation in January 2019 and zheng Tianqing was approved as the second in China in September 2020.
Kapetha bin tablets and other 14 generic drugs through the consistent evaluation of the 19th, the official website of the State Drug Administration shows that Zhengda Qing Kapatebin tablets, four-ring pharmaceutical gaba spray capsules and other 14 drugs recently passed / as if through the consistency evaluation.
Kapeta bin tablets, Gabba spray capsules for the domestic 3rd, Reglinai tablets, hydrochloric acid Prakso slow release tablets, hydrochloric acid Sinacase tablets are the second in the country, hekmos ointment is the first in the country.
Xinhua) -- The Lancet sub-issue publishes the clinical results of the 1/2 issue of the Beijing Bio-New Coronary Inactivated Vaccine, The Lancet-Infectious Diseases, which recently published the clinical development progress of another new corona inactivated vaccine in China, BBIBP-CorV.
phase 1/2 trial, the vaccine candidate showed good safety in all healthy subjects aged 18-80 and successfully induced an immune response.
, the antibody titration induced by the two enhanced vaccination programmes is more ideal.